0000000000021403

AUTHOR

Agostino Gaudio

0000-0002-9958-9606

showing 6 related works from this author

Insights from Experiences on Antiplatelet Drugs in Stroke Prevention: A Review

2020

Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) represents the hard point to be achieved from primary or secondary preventive strategy in the best clinical practice. However, results from clinical trials, recommendations, guidelines, systematic review, expert opinions, and meta-analysis debated on the optimal pharmacotherapy to achieve the objective. Aspirin and a number of antiplatelet agents, alone or in combination, have been considered from large trials focused on stroke prevention. The present review summarizes, discusses results from trials, and focuses on the benefits or disadvantages originating from antiplatelet drugs. Sections of the r…

Malemedicine.medical_specialtyaspirinHealth Toxicology and Mutagenesisdipyridamolelcsh:MedicineStroke.Review030204 cardiovascular system & hematology03 medical and health sciencesTherapeutic approach0302 clinical medicinePharmacotherapyDouble-Blind MethodpreventionSecondary PreventionmedicineHumanscardiovascular diseasesIntensive care medicineStrokeAgedclopidogrelAspirinPreventive strategybusiness.industrylcsh:RPublic Health Environmental and Occupational HealthMiddle AgedClopidogrelmedicine.diseasestrokecombined drug therapyClinical trialDiabetes Mellitus Type 2Ischemic Attack TransientStroke preventionDrug Therapy CombinationFemalebusinesscilostazolPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

What changed in the Italian internal medicine and geriatric wards during the lockdown

2021

A total of 48 internal medicine or geriatric wards among the 93 adhering to the register REPOSI answered an online questionnaire aimed to investigate the characteristics and activities of converted and non-converted wards in the crucial period of the first wave of the epidemic, 22 February-4 May 2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Aged; Humans; Italy; Hospitals; Internal MedicineMEDLINEgeriatricSocio-culturalelaw.inventionlockdownHospitalPatient TransportlawPandemicHospital dischargemedicineInternal MedicineAged Hospitals Humans Internal Medicine ItalyHumansLetter to the EditorInternal medicineAgedLS7_9business.industrygeriatric patientsmedicine.diseaseIntensive care unitHospitalsInternal medicine geriatric patients lockdown covid-19Italycovid-19Medical emergencybusinessHuman
researchProduct

Inter-relationship between platelet-derived microparticles and oxidative stress in patients with venous thromboembolism

2020

Background: Hypercoagulative conditions play a key role in venous thromboembolism (VTE). Inflammation is currently linked to VTE, but the potential role of circulating microparticles and oxidative stress (OxS) must be elucidated. The aim of this study was to evaluate platelet-derived microparticles and surrogate OxS biomarkers in patients diagnosed with VTE through a case&ndash

medicine.medical_specialtyPhysiologyThiobarbituric acidvenous thromboembolismClinical Biochemistry030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryGastroenterologyPathophysiologyArticleSuperoxide dismutase03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePlatelet degranulationInternal medicinemedicineTBARSoxidative stressPlateletcardiovascular diseases030212 general & internal medicineMolecular BiologymicroparticlesVenous thromboembolism.biologybusiness.industrylcsh:RM1-950PlateletbiomarkersCell BiologyBiomarkerequipment and suppliesMalondialdehydelcsh:Therapeutics. PharmacologyClotting timechemistryMicroparticleplateletsbiology.proteinOxidative strebusinessOxidative stress
researchProduct

Pulse wave velocity differs between ulcerative colitis and chronic kidney disease

2017

Background: We hypothesized that a reversal of the physiological stiffness gradient, previously reported in end-stage renal disease, begins in the early stages of chronic kidney disease (CKD) and that chronic inflammation produces a different arterial phenotype in patients with ulcerative colitis (UC). Objectives: To assess the extent of arterial stiffening in the central (carotid-femoral pulse wave velocity, cf.-PWV) and peripheral arteries (carotid-radial pulse wave velocity, cr-PWV) and to explore the determinants of the stiffness gradient in UC and in CKD. Methods: We enrolled 45 patients with UC, 45 patients with stage 3-4 CKD and 45 matched controls. Results: Despite the comparable cf…

MalePathologyDisease030204 cardiovascular system & hematologyurologic and male genital diseases0302 clinical medicine030212 general & internal medicineStage (cooking)ChildPulse wave velocityAged 80 and overArterial stiffness; Chronic renal failure; Inflammation; Pulse wave velocity; Stiffness mismatch; Ulcerative colitis; Internal MedicineMiddle AgedUlcerative colitisArterial stiffnessPeripheralArterial stiffnecardiovascular systemCardiologyFemalemedicine.symptomGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentInflammationPulse Wave Analysis03 medical and health sciencesYoung AdultVascular StiffnessInternal medicinemedicineChronic renal failureInternal MedicineHumansRenal Insufficiency ChronicAgedInflammationUlcerative colitibusiness.industrymedicine.diseasePulse wave velocityCross-Sectional StudiesUlcerative colitisCase-Control StudiesMultivariate AnalysisArterial stiffnessLinear ModelsColitis UlcerativeStiffness mismatchbusinessKidney disease
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

Preventing bone loss during androgen deprivation therapy for prostate cancer: Early experience with neridronate

2005

Abstract Objective: Androgen-deprivation therapy (ADT) is the usual treatment for locally advanced or metastatic prostate cancer. Osteoporosis is a common complication of ADT. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate to prevent bone loss during androgen ablation. Methods: Sixty patients with prostate cancer and osteoporosis were enrolled and randomly assigned to 2 different treatment regimes: group A (30 patients) treated with maximum androgenic blockage (MAB), and group B (30 patients) treated with bicalutamide 150mg. Each group was divided in 2 subgroups A1–A2 and B1–B2. All patients received calcium and cholecalciferol supplements …

Malemusculoskeletal diseasesmedicine.medical_specialtyDeoxypyridinolineBone densityBicalutamideUrologymedicine.medical_treatmentOsteoporosisUrologyImmunoenzyme TechniquesTosyl CompoundsAndrogen deprivation therapyProstate cancerchemistry.chemical_compoundAbsorptiometry PhotonBone DensityNitrilesmedicineHumansNeridronic acidAnilidesTestosteroneAmino AcidsVitamin DChromatography High Pressure LiquidAgedAged 80 and overDiphosphonatesEstradiolbusiness.industryProstatic NeoplasmsAndrogen AntagonistsPhosphorusBisphosphonatemedicine.diseaseSurgeryTreatment OutcomechemistryParathyroid HormoneOsteoporosisCalciumDrug Therapy CombinationbusinessBiomarkersFollow-Up Studiesmedicine.drug
researchProduct